Seegene reports H1 2022 financial results
* H1 revenue fell 11% YoY to KRW 579.9 billion, operating profit down 37% to KRW 212.7 billion * Decline due to drop in Q2 sales amid reduced PCR testing volume * Sales of non-COVID products and PCR instruments increased in H1; Company launches STARlet-AIOS to strengthen sales foundation *...
Seegene unveils strategies for global expansion at 2022 AACC
Company has taken part in the Annual Scientific Meeting & Clinical Lab Expo since 2007 This year's event showcased its In-life PCR campaign and STARlet-AIOS Seegene also displayed Novaplex™ assays, including a test for detecting the monkeypox virus SEOUL, South Korea, July 29, 2022 /PRNewswire/...
Seegene launches world's first In-life PCR campaign in Vietnam
* Test center LabHouse and ride-hailing service Grab to start PCR testing for Grab drivers in August * Seegene to provide Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay to simultaneously detect COVID-19, flu, cold * Testing to begin with drivers in Ho Chi Minh, Hanoi and will later be expanded to ...
Seegene to pave way for PCR testing at local clinics with EU-approved multiplex test and fully automated PCR solution
SEOUL, South Korea, June 29, 2022 /PRNewswire/ -- Seegene Inc. (KQ096530), South Korea's leading molecular diagnostics (MDx) company, has obtained EU approval for its Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay that is compatible with the company's fully automated 'AIOS' (All-in-One System). This is ...
Seegene develops PCR test to detect monkeypox virus
* Assay targets monkeypox virus and can deliver results in 90 minutes * Company swiftly rolls out product using its automated assay development system * "Seegene will strive to make accurate tests for emerging viruses to help prevent future pandemics" SEOUL, South Korea, June 28, 2022 /PRN...
Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic
Includes asymptomatic testing at community-based facilities to prevent widespread transmissions Regular testing for COVID-19, flu, RSV crucial for staying safe as anti-virus restrictions are eased PCR tests will be priced affordably, made possible through Seegene's 20 years of expertise "Full ...
Seegene reports first quarter 2022 financial results
* Q1 revenue up 10% QoQ to reach record quarterly high of KRW 451.5 billion * Foundation for sales expansion strengthened through '3 Ct' technology commercialization, Allplex™ RV Master Assay approval, increased PCR instrument sales * "Seegene to secure future growth by targeting syndromic t...
Seegene unveils world's first commercialized '3 Ct' PCR assay
* Provides Ct value of three targets in one channel; '3 Ct' PCR assay to launch in H1 * "Dream MDx technology" developed based on Seegene's 20-year expertise; combines 19 different patented technologies, including DPO™, TOCE™, MuDT™ * '3 Ct' to lay foundation for automated syndromic testing ...
Seegene's Allplex™ RV Master Assay receives Australian TGA approval, European CE-IVD mark
* Test detects 21 targets for 19 respiratory viruses in single tube, including COVID-19 and flu * Assay result of Seegene's decades-long know-how, applies DPO∙TOCE∙MuDT technologies * "Optimal solution for safe return to normalcy as distancing restrictions eased" SEOUL, South Korea, April 6...
Seegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiary
SEOUL, South Korea, March 17, 2022 /PRNewswire/ -- Seegene Inc.
Seegene appoints Richard Creager as CEO of U.S. subsidiary to bolster U.S. business
SEOUL, South Korea, March 2, 2022 /PRNewswire/ -- Seegene Inc.
Seegene unveils new assay optimized for on-site testing in 'living with Covid-19' era
SEOUL, South Korea, Feb. 24, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today, announced the CE-IVD marking of its Allplex™ SARS-CoV-2 fast MDx Assay. This new assay is optimized for the 'living with COVID-19' era, where mass, swift and ...
Seegene Announces Q4 and Full-Year 2021 Financial Results
* Total sales of 2021 stood at KRW 1.37 trillion, a 22% increase YoY * Q4 Revenue of KRW 410 billion, up 34% QoQ * Operating profit held steady YoY at KRW 666.7 billion despite its tripled strategic investments in R&D * Seegene to make a strategic shift to a 'molecular diagnostics(MDx) plat...
Seegene Signs Supply Deal to Deliver 4 million COVID-19 Tests to Brazil
SEOUL, South Korea, Feb. 10, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, today announced that it has signed a supply deal with the Ministry of Health ofBrazil to deliver four million COVID-19 tests. Since January 2022, Brazil has battled a...
Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing
SEOUL, South Korea, Jan. 19, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today the upcoming launch of the Allplex™ SARS-CoV-2 Fast PCR Assay, which can deliver PCR results in just 60 minutes. The company says that this assay is exp...
Seegene Continues to Support Israel's Effort to Manage the Omicron Variant With Timely Delivery of Five Million Tests
SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today that it has delivered over five million COVID-19 tests toIsrael to help detect and mitigate the spread of the Omicron variant. The company sent 1.7 mill...
Seegene's Allplex™ SARS CoV-2 FluA/FluB/RSV Assay approved under Health Canada's Interim Order
SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, announced it has received approval of its Allplex™ SARS CoV-2 FluA/FluB/RSV Assay under Health Canada's Interim Order onJanuary 11. Seegene's Allplex™ SARS CoV-2 Flu...
Seegene Unveils Blueprint for the Future of Molecular Diagnostics, Including Open Development Platform at the 40th Annual J.P. Morgan Healthcare Conference
SEOUL, South Korea, Jan. 13, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics (MDx) company, today, unveiled its blueprint for the future during a presentation at the 40th annual J.P. Morgan Healthcare virtual Conference. Dr.Jong-Yoon Chun, CEO of Seegene...
Seegene Airlifts 1.7 million COVID-19 Tests to Israel Battling the Omicron Variant by a charter plane
* On December 29, Seegene to deliver Allplex™ SARS-CoV-2 Master Assay that can preemptively detect the Omicron variant at the primary screening stage * Earlier this month, the company has hired a private plane to deliver 2.8 million COVID-19 diagnostic tests to European countries includingItal...
Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube
SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today unveiled another series of diagnostic test that detects the ever-changing COVID-19 variant landscape. The Novaplex™ SARS-CoV-2 Variants VII assay addresses Omicron...
